Hepatitis B virus (HBV) DNA clones were propagated from 57 carriers with antibody to hepatitis B e antigen (HBeAg) and sequenced within nucleotides (nt) 1685 to 1926 including the core promoter (nt 1742 to 1849) and the pre-C region (nt 1814 to 1900). Mutations in the core promoter or those in the pre-C region, or both, were detected in 328 (97.9%) of 335 clones from them. Five carriers were infected with HBV mutants with mutations in the core promoter alone, while 20 carriers were infected only with those in the pre-C region to abort the translation of HBeAg precursor; the remaining 32 carriers were infected with HBV mutants with mutations in both the core promoter and pre-C region. Some carriers infected with HBV with mutations in the core promoter exclusively had high HBV DNA titers, comparable with those in carriers infected with wild-type HBV, thereby indicating that such mutations would not affect the transcription of the HBV pregenome extensively. Two point mutations in the core promoter, from A to T at nt 1762 and from G to A at nt 1764, were most prevalent. The other mutations included a point mutation at either of the two nucleotides and their deletion. All of these mutations involved the TTAAA sequence (nt 1758 to 1762) at 28 bp upstream of the initiation site for shorter pre-C mRNAs (nt 1790 1). The ATAAATT sequence (nt 1789 to 1795) at 23 bp upstream of the initiation site for the pregenome RNA (nt 1818), however, remained intact in all 335 HBV DNA clones. HBV mutants with mutations in the core promoter, unaccompanied by pre-C mutations, prevailed and replaced wild-type HBV in two carriers as they seroconverted from HBeAg to the corresponding antibody. These results indicate that HBV mutants with an HBeAg-phenotype would be generated by mutations in the core promoter which might abort the transcription of pre-C mRNA but do not seriously affect that of pregenome RNA.
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The precursor of hepatitis B e antigen (HBeAg) is coded for by the pre-C region and the C gene (13, 23, 28) . It loses the amino-terminal 19 amino acids (2) and carboxyl-terminal 34 amino acids (32) for the secretion from hepatocytes and circulates in association with plasma proteins such as albumin and immunoglobulins (31) . During persistent hepatitis B virus (HBV) infection, carriers seroconvert from HBeAg to the corresponding antibody (anti-HBe). The seroconversion has significance on both HBV and hosts (14) . In general, HBV replicates more actively in carriers with HBeAg than those with anti-HBe. Carriers with HBeAg have a higher activity to transmit HBV than those with anti-HBe, typically in the perinatal transmission of carrier state from mother to baby (19) .
HBV DNA clones from carriers who have seroconverted to anti-HBe have mutations in the pre-C region which abort the synthesis of HBeAg (3, 21) . The seroconversion from HBeAg to anti-HBe, therefore, is believed to be induced by the immune pressure of hosts against wild-type HBV with an HBeAg+ phenotype toward the predominance of mutants with an HBeAg-phenotype. Not all carriers with anti-HBe harbor pre-C mutants (16) , however, indicating the abrogation of HBeAg synthesis by mutations not affecting the pre-C region.
HBeAg is translated from pre-C mRNAs of 3.5 kb (17, 22, 39) . The other 3.5-kb mRNA (pregenome-C/P mRNA), which initiates 29 to 35 bp downstream of pre-C mRNA start points, is the viral pregenome (38) , from which the core (C) and polymerase (P; DNA polymerase-reverse transcriptase) proteins are translated. The transcription of these mRNAs is controlled by the basic core promoter (BCP) and core upstream regulatory sequences (CURS) (41) . Recently, a negative regulatory element that abolishes the function of CURS on BCP was described (12) .
HBV mutants with an HBeAg-phenotype would be generated by mutations which interfere with the transcription of pre-C mRNA but do not affect that of pregenome-C/P mRNA. HBV DNA clones were propagated from HBV carriers with anti-HBe or HBeAg to determine whether they had mutations in the core promoter or pre-C region to interfere with the expression of HBeAg at either the transcriptional or translational level. 38) were propagated from the 82 sera and sequenced within the core promoter and pre-C region. Pre-C region sequences have been reported for HBV DNA clones from five asymptomatic carriers with HBeAg and three with anti-HBe and from three patients with HBeAg (1, 21, 33) .
MATERUILS AND METHODS
Sera from two carriers with HBeAg were tested for HBV DNA clones with mutations repeatedly while they seroconverted to anti-HBe. Also studied were a carrier mother with anti-HBe in serum and a baby born to her. Because she was positive for anti-HBe with little activity to transmit the persistent carrier state to offspring (19) , the baby was not protected by hepatitis B immunoglobulin or vaccine. Unfortunately, hepatitis B surface antigen (HBsAg) developed in the baby 9 months after birth. HBV DNA clones propagated from sera of the mother taken 12 months after delivery and from the baby at the first appearance of HBsAg were sequenced within the core promoter and pre-C region.
Serological markers of HBV infection. HBeAg and anti-HBe were determined by enzyme-linked immunosorbent assay with commercial kits (HBeAg/Ab EIA; Institute of Immunology Co., Ltd., Tokyo, Japan). HBsAg and the corresponding antibody were determined by hemagglutination with commercial kits (MyCell; Institute of Immunology). Antibody to hepatitis B core antigen (anti-HBc) was determined by inhibition of hemagglutination (7) . The results of hemagglutination assays were expressed by the highest twofold dilution (2") of sera which induced or inhibited hemagglutination.
Determination of HBV DNA. Nucleic acids were extracted from 0.1 ml of serum with phenol-chloroform in the presence of proteinase K-sodium dodecyl sulfate by a method described elsewhere (21) . They were diluted 10-fold serially with TrisHCl buffer (10 mM, pH 8.0) supplemented with 1 mM EDTA and 20 jig of glycogen (Boehringer, Mannheim, Germany) per ml. HBV DNA was amplified by PCR with nested primers deduced from the S gene (7) , and the highest dilution (10") in which it was detectable was determined.
Amplification of a part of the X gene and pre-C region. On HBV DNA extracted from serum, a fragment of 263 bp corresponding to nucleotides (nt) 1679 to 1941 was amplified by PCR with nested primers which included enhancer II (nt 1685 to 1773 [36] ), BCP (nt 1742 to 1849 [41] ), and the 3'-terminal 64% of CURS (nt 1643 to 1742 [41] ), as well as the pre-C region (nt 1814 to 1900) (Fig. 1) ; nucleotides are numbered from the unique EcoRI site in HBV DNA (21 cTwo (22%) of the clones were without mutations in the core promoter or pre-C region. d Two (25%) of the clones were without mutations in the core promoter or pre-C region.
Mutations in 155 clones from HBeAg-positive patients with chronic hepatitis are shown in Table 4 . Mutations in the core promoter were detected in all clones from patients 2, 8, and 10 and in some clones from the remaining eight patients. The G-to-A point mutations at nt 1896 was found in some clones from four patients.
Mutations in the core promoter and induced amino acid changes. Patterns of point mutations in the core promoter are illustrated in Fig. 2 , and induced amino acid changes are shown in Fig. 3 Three AT-rich regions were identified in the core promoter (Fig. 2) Table 8106 OKAMOTO ET AL. (41), CURS (41) , and a negative
The three patients with mutants with invariable mutations in regulatory element have been identified in the X gene (12) . the core promoter might have been seroconverting to antiThe liver-specific enhancer II overlaps with BCP and CURS HBe; some HBV DNA clones from two of them had mutations (36, 40, 42) . Should mutations in the X gene involve any of in the pre-C region. HBeAg in their sera might be attributable these essential elements, they would modify the replication of to coinfecting wild-type HBV that escaped detection, which (sex") titer tested -GTAGGCATAAATTGGTCTGTTCACCAGCACCA Table 3 and patient 11 in Table 4 ) had two distinct mutants with different patterns of mutations.
would have to be searched for by PCR with specific primers. Some HBV DNA clones from two asymptomatic carriers (carriers 2 and 10 in Table 1 ) and two patients with chronic hepatitis B (patients 4 and 14 in Table 2 ), all of whom were positive for anti-HBe, had no mutations in the pre-C region or the core promoter. HBeAg would have occurred in their circulation but escaped the detection because it complexed with antibodies.
Mutations affecting the core promoter in 32 (86%) of 37 carriers with anti-HBe were found in association with pre-C mutations, which can abort the synthesis of the HBeAg precursor (3, 21) . The remaining five anti-HBe-positive carriers, however, were infected with HBV mutants with mutations in the core promoter unaccompanied by mutations in the pre-C region. This finding indicates that mutations in the core GEEIRLKVFVwGGCmnHIVCSPAPCNFFTSA promoter, by themselves, would be able to induce an HBeAgphenotype. It is possible that mutations in the core promoter would disturb the transcription of pre-C mRNA for an HBeAg-phenotype, so that the hepatocytes harboring mutants may escape the immune elimination by anti-HBe responses of hosts.
HBV DNA clones with mutations in the core promoter unaccompanied by pre-C mutations gradually prevailed in two carriers as they seroconverted from HBeAg to anti-HBe and finally replaced wild-type HBV. Such a gradual shift, from wild-type HBV to pre-C mutants, is observed in carriers who seroconvert to anti-HBe (21) . Mutations in the core promoter and those in the pre-C region co-occurred frequently, and they would collaborate toward the seroconversion to anti-HBe. The second G-to-A mutation at nt 1899 in the pre-C region, which is reported in HBV DNA clones with an HBeAg-phenotype (3), was rather rare in HBV DNA clones with the G-to-A mutation at nt 1896 from the carriers studied.
Typical patterns emerged for mutations in the core promoter. Most frequent were an A-to-T mutation at nt 1762 and a G-to-A mutation at nt 1764, which were detected in HBV DNA clones from 40 (82%) of 49 carriers with core promoter mutants. Without point mutations in these hot spots, clones from some carriers possessed an 8-, 20-, or 21-bp deletion which involved both nt 1762 and nt 1764. All of these mutations affected the second of the three AT-rich regions in the core promoter, which is positioned 27 to 29 bp upstream of the transcriptional initiation sites (nt 1790 ± 1) for shorter pre-C mRNAs (39) . AT-rich regions are detected about 25 bp upstream of the mRNA start points in cellular and viral promoters (4) , and they are thought to bind with RNA polymerase for initiating transcription. Should the observed mutations in the core promoter interfere with the transcription of pre-C mRNA, they would disturb the synthesis of HBeAg. Fig. 2. b A female asymptomatic carrier who was 29 years old at the date of the last sampling (corresponds to carrier 1 in Table 1 ). c A male patient with chronic hepatitis who was 54 years old at the date of the last sampling (corresponds to patient 3 in Table 2 ).
This view is supported by the low in vitro expression of HBeAg by HBV mutants with an 8-bp deletion in the X gene (25) . Point mutations in the TATA sequence motif in eucaryotic promoters drastically decrease specific in vitro transcription (15, 37) . Should this negative influence be extended to AT-rich regions in viral promoters, the change of the last A for T in the second AT-rich region (TTAAA) of most clones with mutations in the core promoter would be expected to decrease the transcription of shorter pre-C mRNAs starting at nt 1790 ± 1. The validity of this hypothesis could be evaluated by transfecting hepatoma cell lines with HBV mutants with various mutations involving the second AT-rich region in the core promoter for the expression of HBeAg.
The third AT-rich region (ATAAATT), which is preserved very well in reported HBV isolates, is proposed for the transcription of pregenome-C/P mRNA 23 bp downstream of it (39) . It is remarkable that the third AT-rich region remained intact in all 766 HBV DNA clones from the 82 carriers examined. This observation reflects the indispensability of the ATAAATT sequence for transcription of the HBV pregenome and suggests distinct controls of pregenome-C/P mRNA and pre-C mRNAs for the evolution of HBV mutants with an HBeAg-phenotype. An anti-HBe-positive carrier mother transmitted HBV to her baby perinatally. Both mutants with mutations in the core promoter and pre-C mutants were detected in the mother. Mutants with mutations in the core promoter were found exclusively in the baby, who had hightitered HBV DNA without detectable HBeAg or anti-HBe in serum. These results indicate that HBV mutants with mutations in the core promoter are replication competent and that they would not be able to direct the synthesis of HBeAg in hosts. The possibility of HBeAg complexed with anti-HBe, preventing the detection of either antigen or antibody, needs to be excluded, however.
Some arguments against our hypothesis have to be addressed. HBV DNA clones with the core promoter mutations were detected predominantly or exclusively in some HBeAgpositive carriers. This finding indicates that mutations in the core promoter would reduce but probably not eliminate the expression of HBeAg. More importantly, the core promoter mutations could have reduced the level of all mRNAs derived from the core promoter rather than selectively inhibited pre-C mRNA transcription, which in effect reduces the production of HBeAg for anti-HBe seroconversion. High serum HBV DNA titers were observed in some carriers with anti-HBe who were infected with the core promoter mutants exclusively, as well as in a carrier who had seroconverted from HBeAg to anti-HBe along with gradual shift from wild-type HBV to core promoter mutants in his circulation, however. They suggest that mutations in the core promoter might not seriously affect transcription of the HBV pregenome. In vitro transfection studies are required to examine the effect of various core promoter mutations on the level of expression of various transcripts derived from the core promoter before our hypothesis is validated.
The product of the X gene transactivates viral and host genes (29, 30, 35) . Observed mutations in the core promoter may or may not affect the transactivating function of the X protein. High HBV DNA levels in some anti-HBe-positive patients infected with mutants with mutations in the core promoter indicate that such mutations would have little, if any, influence on transactivation of the core promoter.
The G-to-A point mutation at nt 1896 in the pre-C region is proposed to be dependent on HBV genotypes, because it b Mutations were of pattern j in Fig. 2 .
c G-to-A point mutation at nt 1896 to abort the synthesis and secretion of HBeAg; it was detected in all four clones without mutations in the core promoter. d Corresponds to carrier 11 in Table 1 .
